Economic aspects of sublingual immunotherapy

Area of Science:

• Allergy and Immunology
• Pharmacoeconomics
• Public Health

Background:

• Allergic rhinitis and asthma are highly prevalent, imposing significant medical and economic burdens.
• Specific immunotherapy (IT) can favorably alter disease progression and reduce associated costs.
• Previous studies demonstrated cost reductions with subcutaneous immunotherapy (SCIT).

Purpose of the Study:

• To analyze existing studies on the economic evaluation of sublingual immunotherapy (SLIT) in pediatric and adult patients.
• To assess the cost-effectiveness and economic benefits of SLIT compared to standard treatments and SCIT.

Main Methods:

• A systematic literature search was conducted in Medline and Embase.
• Keywords included "economic aspects," "pharmacoeconomics," "cost effectiveness," and "sublingual immunotherapy."
• 18 relevant English-language articles were identified, with 7 focusing on SLIT's economic advantage over drug treatment and 2 comparing SLIT and SCIT costs.

Main Results:

• Seven studies indicated economic advantages of SLIT over standard drug treatments for respiratory allergies.
• Two studies comparing SLIT and SCIT suggested potential cost savings with SLIT.
• SLIT is associated with economic benefits and cost reductions, particularly in alleviating the disease's economic burden.

Conclusions:

• Available evidence suggests that sublingual immunotherapy (SLIT) provides economic advantages for managing respiratory allergies.
• While the number of studies is limited, SLIT shows potential for cost savings in allergy treatment.
• Further research into the pharmacoeconomics of SLIT is warranted to confirm its long-term economic impact.